WASHINGTON -- The FDA approved a new formulation of the drug bimatoprost (Lumigan) in a 0.01% solution as a first-line treatment to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Approval was based on a three-month clinical trial of patients with open-angle glaucoma or ocular hypertension, with an average baseline intraocular pressure...



